Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2084198 | 0.92 | PREP (0.48) | PREP | |
| SCHEMBL2084143 | 0.86 | PREP (0.47) | PREP | |
| SCHEMBL1816285 | 0.84 | PREP (0.51) | PREP | |
| SCHEMBL28943687 | 0.84 | PREP (0.51) | PREP | |
| SCHEMBL2082334 | 0.82 | FOLH1 (0.49) | — | |
| SCHEMBL2084495 | 0.82 | PREP (0.45) | PREP | |
| SCHEMBL1189714 | 0.81 | PREP (0.50) | PREP | |
| SCHEMBL17293555 | 0.80 | PREP (0.49) | PREP | |
| SCHEMBL1816147 | 0.80 | PREP (0.49) | PREP | |
| SCHEMBL2084231 | 0.80 | PREP (0.48) | PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863304-B2 | Analogs of glycyl-prolyl-glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2011-01-04 | — | — | US | disclosed |
| US-20080145335-A1 | Analogs of Glycyl-Prolyl-Glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080145335-A1 | Analogs of Glycyl-Prolyl-Glutamate | GLS, GLUL, HIF1A | PREP 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.